Online inquiry

IVTScrip™ mRNA-Anti-TNF, OPRX-106(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12880MR)

This product GTTS-WQ12880MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets TNF gene. The antibody can be applied in Non-alcoholic steatohepatitis (NASH) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000594.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7124
UniProt ID P01375
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNF, OPRX-106(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ12880MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5678MR IVTScrip™ mRNA-Anti-GPNMB, CDX-011 (DOX)(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CDX-011 (DOX)
GTTS-WQ8623MR IVTScrip™ mRNA-Anti-CD33, HuM195(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA HuM195
GTTS-WQ14194MR IVTScrip™ mRNA-Anti-ANGPT2, REGN-910(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA REGN-910
GTTS-WQ6971MR IVTScrip™ mRNA-Anti-pagA, ETI-204(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ETI-204
GTTS-WQ5887MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, CIFN(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CIFN
GTTS-WQ7842MR IVTScrip™ mRNA-Anti-RTN4, GSK-1223249(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA GSK-1223249
GTTS-WQ10108MR IVTScrip™ mRNA-Anti-MET, LA480(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LA480
GTTS-WQ680MR IVTScrip™ mRNA-Anti-CD276, 8H9(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA 8H9
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW